INmune BioINMB
INMB
About: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Employees: 13
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
483% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 6
369% more call options, than puts
Call options by funds: $1.78M | Put options by funds: $379K
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
8% more funds holding
Funds holding: 66 [Q3] → 71 (+5) [Q4]
3.69% more ownership
Funds ownership: 24.14% [Q3] → 27.83% (+3.69%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0% less capital invested
Capital invested by funds: $28.8M [Q3] → $28.8M (-$18.9K) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
194%
upside
Avg. target
$27
239%
upside
High target
$30
284%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Jason McCarthy 16% 1-year accuracy 5 / 32 met price target | 284%upside $30 | Buy Maintained | 13 Feb 2025 |
Scotiabank George Farmer 19% 1-year accuracy 4 / 21 met price target | 194%upside $23 | Sector Outperform Maintained | 11 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system has partnered with the Cell and Gene Therapy Catapult (CGT Catapult) to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK.
Neutral
Seeking Alpha
1 month ago
INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer Christopher Barnum - Head of Neuroscience Conference Call Participants George Farmer - Scotiabank Thomas Shrader - BTIG Denis Reznik - Raymond James Elemer Piros - Rodman James Molloy - Alliance Global Partners Operator Greetings, and welcome to the INmune Bio's. 2024 Fourth Quarter and Full Year Earnings Call.
Neutral
GlobeNewsWire
1 month ago
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended December 31, 2024 and provides a business update.
Neutral
Seeking Alpha
1 month ago
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh ideas and fostering discussion among investors. Mitsui & Co. is given a 'buy' recommendation, driven by Warren Buffett's increased stake, stable commodity prices, and promising long-term growth from a new Australian iron ore deal. Sandisk Corporation is also seen as a 'buy' post-separation from Western Digital, with strong market performance and potential for unlocking shareholder value as an independent flash storage company.
Positive
Seeking Alpha
1 month ago
INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results
INmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billion valuation if successful, offering a 135x stock upside. CORDstrom may act as a fail-safe for INmune Bio's stock if XPro fails, ensuring a high likelihood of substantial returns.
Neutral
GlobeNewsWire
2 months ago
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort.
Neutral
GlobeNewsWire
2 months ago
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients.
Positive
Seeking Alpha
3 months ago
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025
INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial for XPro in Alzheimer's is fully enrolled, with topline data expected around May-June 2025, marking a pivotal moment. XPro's selective TNF inhibition has shown significant reductions in key biomarkers like ptau-217 and neurofilament light, indicating strong efficacy in neurodegenerative diseases.
Negative
Seeking Alpha
3 months ago
INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers
INmune Bio, Inc.'s decline in 2024 is attributed to broader biotech sector issues, lack of significant clinical data, and inherent risks in Alzheimer's research. XPro, INMB's lead candidate, shows potential in early-stage trials for Alzheimer's, with crucial phase 2 data expected in Q2 2025. Financially, INMB has limited runway, with cash sufficient to fund operations only into Q3 2025, necessitating successful trial outcomes for further funding.
Neutral
Business Wire
4 months ago
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
HOUSTON & BOCA RATON, Fla.--(BUSINESS WIRE)--OmniScience and INmune Bio (NASDAQ: INMB) today announced a pioneering partnership to revolutionize operations for INmune Bio's global Phase 2 Alzheimer's disease (AD) clinical trial (the “AD02 trial”) using OmniScience's flagship product, Vivo, an industry-first, genAI-powered control tower designed specifically for centralizing and analyzing vast clinical data in real time. This solution represents an innovative approach to clinical research, deliv.
Charts implemented using Lightweight Charts™